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Background: Colorectal cancer (CRC) sidedness is predictive of anti-epidermal growth factor receptor (anti-EGFR) anti-
body therapy effectiveness; however, the mechanism linking them is unclear. Long interspersed nuclear element-1 (LINE-1)
methylation has been associated with sidedness. Here, we evaluated whether LINE-1 expression in CRC cell lines influenced
the efficacy of EGFR inhibitors.
Methods: We analyzed LINE-1 methylation in 98 clinical CRC samples. We also treated RAS-wild type SW48 and Caco-2
and RAS-mutant SW480, HCT116, and DLD-1 CRC cell lines with EGFR inhibitors gefitinib or RG14620, and performed
growth assays in LINE-1-suppressed Caco-2, SW480, and DLD-1 cells.
Results: Clinical CRC findings confirmed the association between LINE-1 methylation and sidedness. LINE-1 mRNA ex-
pression was high in SW480 and Caco-2 cells and low in HCT116 and SW48 cells. The half maximal inhibitory concentra-
tions (IC50) of gefitinib were lower for LINE-1-expressing Caco-2 cells than for non-LINE-1-expressing SW48 cells, reveal-
ing an association between LINE-1 expression and the efficacy of gefitinib in RAS-wild type cells. LINE-1 knockdown in-
creased the IC50 of gefitinib in Caco-2 cells. There was trend of increase in RG14620 IC50 upon LINE-1 knockdown even in
RAS-mutant SW480 and DLD-1 cells, suggesting other mechanisms of RG14620 than EGFR signal inhibition.
Conclusion: EGFR inhibitor gefitinib requires LINE-1 expression, and interventions targeting LINE-1 may increase its effi-
cacy.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer-
related deaths worldwide. Recent advances in anticancer
drug therapy have improved the prognosis for patients
with inoperable CRC. However, a substantial proportion
of CRC patients receive anticancer drug therapy without
benefit because the effects are unpredictable. To avoid
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ineffective therapy, predictive markers for anticancer
drug therapy are required.
RAS mutational status (RAS status) is the most suc-
cessful biomarker of the efficacy of anti-EGFR antibody
therapy for CRC.
１，２
In addition to the RAS status of CRC,
recent clinical data have shown that CRC left-sidedness
is associated with higher sensitivity to anti-epidermal
growth factor receptor (anti-EGFR) antibody than right-
sidedness.
３
Sidedness is already considered important in
several clinical guidelines for decision-making for CRC
therapy.
４
However, it is only a surrogate marker for the
effectiveness of the anti-EGFR antibody. The biological
mechanism underlying the association between sidedness
and sensitivity to anti-EGFR antibody is still unclear.
Long interspersed nuclear element-1 (LINE-1) is the
most abundant transposable element in the human
genome, accounting for 17% of the entire human
genome.
５-７
The methylation of LINE-1 is reportedly re-
lated to the localization of CRC, with higher LINE-1
methylation levels in right-sided than in left-sided
CRC.
８-１０
DNA methylation is known to regulate gene ex-
pression by influencing chromatin structure. Abundant
DNA methylation leads to a tight chromatin structure that
prevents gene expression.
１１，１２
Both the effects of EGFR inhibitors and LINE-1 ex-
pression correlate with CRC localization, which led us to
hypothesize that LINE-1 expression might be associated
with the effects of EGFR inhibitors. Therefore, in this
study, we investigated the relationship between LINE-1




This study included 98 patients with CRC who re-
ceived chemotherapy at Tokyo Women’s Medical Uni-
versity (Tokyo, Japan). The patients comprised 51 males
and 47 females ranging in age from 48 to 88 years
(mean, 67.8 years). The tumors were classified as right-
sided or left-sided relative to the splenic flexure. A total
of 43 patients were defined as having right-sided CRC
and 55 as having left-sided CRC. Other clinicopathologi-
cal information such as clinical stage and cancer histol-
ogy was also obtained, although the stage in 4 and histol-
ogy in 5 patients were not available at the time of this
study. We obtained tissue samples for RAS mutation and
LINE-1 methylation analysis from formalin-fixed,
paraffin-embedded tumor blocks selected on the basis of
tumor cell content. The tumor tissue was dissected manu-
ally from 10 μm paraffin sections. After deparaffinization
using xylene and ethanol, genomic DNA was extracted
from the tissue using QIAamp
Ⓡ
DNA Mini Kits (Qiagen,
Hilden, Germany) according to the manufacturer’s proto-
col. This project was approved by the Tokyo Women’s
Medical University Medical Ethics Committee (approval
number 260B).
Cell lines and culture conditions
The CRC cell lines SW48, SW480, HCT116, Caco-2,
RKO, HT-29, DLD-1, LoVo, LS174T, HCT-15, and SW
620 were obtained from the American Type Culture Col-
lection (Manassas, VA, USA). The cells were maintained
at 37°C in a 5% CO2 environment in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal bo-
vine serum and antibiotics (100 U/mL penicillin G and
100 μg / mL streptomycin ; Gibco, Grand Island, NY,
USA). Genomic DNA was extracted from the cell lines
using QIAamp
Ⓡ
DNA Mini Kits (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol.
RAS mutation analysis
Genomic DNA extracted from clinical samples and
cultured cell lines was used for RAS mutation analysis.
The DNA sequence was amplified by polymerase chain
reaction (PCR) for RAS codons 12 and 13, followed by
direct sequencing, as described previously.
２
LINE-1 methylation analysis
Genomic DNA extracted from clinical samples and
cultured cell lines was treated with bisulfite using
EpiTect Bisulfite Kits (Qiagen, Hilden, Germany ) ac-
cording to the manufacturer’s instructions. After bisulfite
treatment, LINE-1 methylation levels were quantitatively
measured using a methylation-specific real-time PCR as-
say as described previously.
１３
Northern blotting




Table　1　Association between location of colorectal cancer and 
LINE-1 methylation level.
Case Location n LINE-1 methylation p-value
Total
Left 55 79.8 (69.8-86.3) 
0.0025
Right 43 84.5 (79.7-90.7) 
RAS-wild type
Left 37 77.3 (68.6-90.7) 
0.012
Right 23 83.4 (78.1-92.4) 
RAS-mutant type
Left 18 80.3 (71.5-89.3) 
0.22
Right 20 85.0 (82.1-88.8) 
LINE-1 methylation levels are shown as median (25th percentile-
75th percentile).
n, number of patients.
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. Polyadenylated RNA was then purified and
northern blotting was conducted as described previ-
ously.
１４
RNA probes for LINE-1 mRNA detection were
synthesized as described previously
１４
and RNA probes
for β-actin were included in the DIG Northern Starter Kit
(Roche, Mannheim, Germany).
RNA interference
Small interfering RNAs ( siRNAs ) specific to the
LINE-1 sequence and non-specific siRNAs were synthe-
sized by NIPPON Gene (Toyama, Japan). The siRNA se-
quences have been described previously.
１４
The cells were
transiently transfected with LINE-1-specific or non-
specific siRNAs using Lipofectamine™ RNAiMAX (In-
vitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. At 24 h after transfection with the re-
spective siRNAs, the cells were treated with dimethyl
sulfoxide or EGFR inhibitors for 72 h. The cell growth
was analyzed by Cell Counting Kit-8 (CCK-8; Dojindo,
Shanghai, China) assay.
CCK-8 assay
We determined the rate of cell proliferation with a
CCK-8 kit according to the manufacturer’s instructions.
Briefly, cells were seeded in a 96-well plate (10
4
cells/
well). Then, the cells were treated with increasing con-
centrations of the EGFR inhibitors gefitinib or RG14620.
The CCK-8 reagent was added, and the optical density at
450 nm was detected using a microplate reader (uQuant,
BioTek, Winooski, VT). The assay was repeated at least
three times and results are shown as mean and standard
deviation.
Statistical analysis
The level of LINE-1 methylation was expressed as a
median value (25th percentile to 75th percentile). The
Mann-Whitney U test was used to compare LINE-1
methylation levels between two variables. Differences in
clinical backgrounds by sidedness was analyzed by chi-
squared test. Half maximal inhibitory concentrations
(IC50) was expressed as mean± standard deviation. One-
way analysis of variance and Tukey’s HSD test were
used to compare the IC50 of four CRC cells treated with
gefitinib and RG14620. Paired t-test was used to com-
pare the IC50 values between cells treated with LINE-1-
specific and non-specific siRNAs. Statistical analyses
were carried out using the R software package.
１５
Results
LINE-1 methylation is lower in left-sided CRC than
in right-sided CRC
We measured LINE-1 methylation levels in clinical
samples by methylation-specific PCR. Table 1 shows the
values for right- and left-sided CRC. Right-sided CRC
samples had a significantly higher LINE-1 methylation
level than left-sided CRC samples. The differences in
LINE-1 methylation associated with the sidedness of
CRC were also evident upon RAS-wild type sample
analysis. Analysis of clinicopathological backgrounds
showed that right-sided CRC was more frequent in elder
and female patients, although the relationship was not
observed when the analysis was limited to RAS-wild type
sample (Table 2) . Clinical stage and cancer histology
were not associated with sidedness of CRC (Supplemen-
tary Table). As the results were consistent with previous
reports,
８-１０
we continued to test the hypothesis that
LINE-1 expression is associated with the effectiveness of
EGFR inhibitors.
LINE-1 methylation level and RAS status in CRC
cell lines
We screened the RAS statuses and LINE-1 methylation
levels of 11 commonly used CRC cell lines (Table 3).
Most cell lines with LINE-1 methylation levels lower
than 50% had RAS mutations. Only Caco-2 was RAS-
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Figure　1　The association between LINE-1 mRNA expression
and sensitivity to EGFR inhibitors in colorectal cancer (CRC) cell
lines. (A) LINE-1 mRNA is expressed in SW480 and Caco-2, but 
not in HCT116 and SW48 cells. RAS status is indicated as wt for
wild type and mt for mutant type. (B) Gefitinib IC50 determined by
CCK-8 assay. (C) RG14620 IC50 determined by CCK-8 assay. P
values calculated by statistical analysis are displayed in the figure.
IC50, half maximal inhibitory concentration. 
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RAS status                mt                    wt                   mt wt
p < 0.001
p < 0.0001 p < 0.0001
p < 0.0001
p < 0.001
p < 0.01 p < 0.01
Table　2　Relation of patients’ age and gender with 





All cases 98 55 43
Age, years
< 69 50 34 16
0.027
69 ≤ 48 21 27
Gender
Male 51 34 17
0.047
Female 47 21 26
RAS-wild type 60 37 23
Age, years
< 69 33 23 10
0.25
69 ≤ 27 14 13
Gender
Male 34 22 12
0.78
Female 26 15 11
RAS-mutant type 38 18 20
Age, years
< 69 17 11 6
0.11
69 ≤ 21 7 14
Gender
Male 17 12 5
0.024
Female 21 6 15
n, number of patients.
Table　3　RAS status and LINE-1 methylation level in colorectal 
cancer cell lines.
Cell line
RAS status  LINE-1 
methylation (%) K-ras codon 12 K-ras codon 13
RKO wt wt 90.2
HCT116 wt G13D 84.1
SW48 wt wt 80.2
HT-29 wt wt 69.5
DLD-1 wt G13D 60.2
LoVo wt G13D 50.3
Caco-2 wt wt 48.2
LS174T G12D wt 47.6
HCT-15 wt G13D 47.5
SW480 G12V wt 43.6
SW620 G12V wt 30.3
Mutation was listed with 1 letter abbreviation of amino acid substi-
tution.
wt, wild type.
Table　4　RAS status and LINE-1 methyla-
tion level of the colorectal cancer cell lines 






wt, wild type; mt, mutant type.
wild type with less than 50% LINE-1 methylation. Based
on the results, we selected 4 cell lines with varying RAS
statuses and LINE-1 methylation levels (Table 4).
Effects of EGFR inhibitors in CRC cell lines
LINE-1 mRNA expression was high in SW480 and
Caco-2 cells, but low in HCT116 and SW48 cells (Fig-
ure 1A), consistent with the LINE-1 methylation levels
in those cells. IC50 of gefitinib was significantly lower in
RAS-wild type, LINE-1-expressing Caco-2 (7.6 ± 0.46
μM) compared to SW480 (22.2 ± 1.8 μM), HCT116
(17.4 ± 0.36 μM), and SW48 (17.2 ± 0.52 μM), sug-
gesting that LINE-1 expression correlates with the gefit-
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Figure　2　LINE-1 mRNA expression in (A) Caco-2 and (B) 
SW480 cells is suppressed by RNA interference. Northern blot
analysis of LINE-1 mRNA are shown in the upper panel with num-
bers reflecting the relative amount of LINE-1 mRNA quantified
by image analysis software, ImageJ, and normalized to β-actin.
Northern blot analysis of β-actin mRNA are shown in the lower
panel. LINE-1 Si is a LINE-1-specific 23-mer double-stranded 
RNA for RNA interference and SiNC is a non-specific sequence. 
LINE-1 
ACTB 
LINE-1 Si          SiNCB
LINE-1 
ACTB 
LINE-1 Si          SiNCA
0.52                          1
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Figure　3　IC50 of gefitinib in (A) Caco-2 and (B) SW480 cells af-
ter LINE-1 suppression by RNA interference. P values calculated
by statistical analysis are displayed in the figure. LINE-1 Si is a 
LINE-1-specific 23-mer double-stranded RNA for RNA interfer-
ence and SiNC is a non-specific sequence. 






















Figure　4　IC50 of RG14620 in (A) Caco-2 and (B) SW480 cells
after LINE-1 suppression by RNA interference. P values calcu-
lated by statistical analysis are displayed in the figure. LINE-1 Si
is a LINE-1-specific 23-mer double-stranded RNA for RNA inter-
ference and SiNC is a non-specific sequence.



























inib sensitivity of CRC cells without RAS mutations. In
contrast, the IC50 of RG14620 was significantly lower in
RAS-wildtype Caco-2 (20.8± 14.3 μM) and SW48 (30.4
± 14.8 μM) compared to RAS-mutant SW480 (123.6 ±
22.4 μM) and HCT116 (92.3± 10.2 μM) independent of
LINE-1 expression. These results suggest that gefitinib
and RG14620 may have different anti-proliferating
mechanism even though both are classified as EGFR in-
hibitors.
Effects of EGFR inhibitors in CRC cell lines are de-
pendent on LINE-1 expression
We analyzed the effects of LINE-1 knockdown by
RNA interference in the LINE-1-expressing cell lines
Caco-2 and SW480 on their sensitivity to EGFR inhibi-
tors. RNA interference successfully suppressed LINE-1
expression (Figure 2) after 48 h of siRNA treatment of
the cells. Knockdown of LINE-1 significantly increased
the IC50 of gefitinib in RAS-wild type Caco-2 cells (14.1
± 3.0 vs. 5.6 ± 1.1 μM, Figure 3A) but had no effect
on RAS-mutant SW480 cells (20.5± 1.3 vs. 19.9± 1.7
μM, Figure 3B). These results suggest that gefitinib re-
quires LINE-1 expression for its anticancer effect in
RAS-wild type cell.
Knockdown of LINE-1 increased the IC50 of RG14620
in Caco-2 (59.1± 32.0 vs. 23.5± 7.1 μM, Figure 4A)
and SW480 cells (136.7± 53.1 vs. 47.0± 9.8 μM, Fig-
ure 4B) although it did not reach statistical significance.
The statistical trend (p = 0.071) in RAS-mutant SW480
cells treated with RG 14620 was unexpected, because
EGFR inhibitor has generally no effect on RAS-mutant
CRC, as observed by gefitinib treatment. Therefore, we
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Figure　5　(A) LINE-1 mRNA expression in DLD-1 cells is sup-
pressed by RNA interference. Northern blot analysis of LINE-1
mRNA are shown in the upper panel with numbers reflecting the 
relative amount of LINE-1 mRNA quantified by image analysis
software, ImageJ, and normalized to β-actin. Northern blot analy-
sis of β-actin mRNA are shown in the lower panel. LINE-1 Si is a 
LINE-1-specific 23-mer double-stranded RNA for RNA interfer-
ence and SiNC is a non-specific sequence. (B) IC50 of RG14620 
in DLD-1 cells after LINE-1 suppression by RNA interference. P
values calculated by statistical analysis are displayed in the figure.
LINE-1 Si is a LINE-1-specific 23-mer double-stranded RNA for 
RNA interference and SiNC is a non-specific sequence.

















0.61                          1
repeated the experiment using another RAS-mutant cell
line. We screened RAS-mutant cell lines and found that
DLD-1 expresses LINE-1 mRNA and the expression was
effectively suppressed by RNAi (Figure 5A) . In RAS-
mutant DLD-1 cells, knockdown of LINE-1 increased
the IC50 of RG14620 (197.3 ± 126.5 vs. 76.6 ± 49.1
μM, Figure 5B), which was close to significance (p =
0.054). These results suggested that LINE-1 expression is
associated with the effectiveness of RG14620 in RAS-
mutant CRC cells.
Discussion
In the present study we explored the association between
the expression of LINE-1 mRNA and the effectiveness of
EGFR inhibitors in CRC cells. The results showed an as-
sociation between LINE-1 expression and the effects of
gefitinib in CRC cells without RAS mutations. However,
Caco-2 was the only RAS-wild type, LINE-1-expressing
line among our screened cell lines. Studies using addi-
tional RAS-wild type, LINE-1-expressing cells are
needed to verify the reproducibility of and extend our
findings.
Although our results are based on an in vitro study us-
ing cell lines, they are clinically important and warrant
further investigation. The suggested relationship between
LINE-1 expression and the efficacy of EGFR inhibitors
may lead to novel therapeutic strategies. Controlling
LINE-1 expression may enhance the effects of EGFR in-
hibitors and overcome therapeutic resistance. In addition,
controlling LINE-1 expression in normal tissue may
overcome the troublesome EGFR inhibitor side effect of
skin rash. Our clinical investigation support the signifi-
cance of LINE-1 expression. Right-sided CRC samples
had a significantly higher LINE-1 methylation level than
left-sided CRC samples when RAS-wild type CRC was
analyzed. The clinical higher response to anti-EGFR anti-
body in left-sided CRC patients may be explained by the
difference in LINE-1 methylation level. Further investi-
gation is needed to clarify the mechanism underlying the
relationship between LINE-1 expression and the effects
of EGFR inhibitors to improve clinical strategies using
EGFR inhibitors for CRC patients.
An unexpected result obtained in our study was the as-
sociation between LINE-1 expression and the effective-
ness of the EGFR inhibitor RG14620 in the RAS-mutant
cell lines, SW480 and DLD-1. These results shed light on
the role of RG14620 in patients with RAS-mutant CRC.
RG14620 was synthesized as a member of tyrphostins,
which are potent EGF receptor kinase inhibitors,
１６
and
has been used as an EGFR inhibitor in research. Recent
study demonstrated that RG14620 also inhibits ABCG2
transporter, reversing multidrug resistance.
１７
The differ-
ence between gefitinib and RG14620 in the current study
may be due to an unknown mechanism of RG 14620
other than EGFR inhibition. Further study of RG14620 is
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required especially on its anti-proliferating effect on
RAS-mutant CRC, because anti-EGFR antibody therapy
is not allowed for RAS-mutant CRC patients, resulting in
limitation of cancer therapy. LINE-1 expression may be
clinically useful to select the patients with RAS-mutant
CRC who could benefit from RG14620.
The development of a diagnostic method to evaluate
LINE-1 expression in clinical samples will be essential to
facilitate the use of LINE-1 expression as a predictive
marker. We used northern blotting to analyze LINE-1
mRNA expression in CRC cell lines. As LINE-1 is a
retroposon that is repeated genome-wide, it would be dif-
ficult to quantitate LINE-1 mRNA by PCR because of
contamination by LINE-1 DNA. Detection of the full-
length 6-Kb mRNA by northern blotting is the most reli-
able method; however, it is complex and, therefore, not
appropriate for clinical diagnosis. One simple diagnostic
method may be immunohistochemistry with a specific
antibody that recognizes a protein translated from
LINE-1 mRNA. LINE-1 mRNA is translated into two
proteins from open reading frame 1 and open reading
frame 2.
１８
Development of a method for easy and reliable
evaluation of LINE-1 protein levels may also highlight
the importance of LINE-1 protein as a clinical marker.
LINE-1 methylation has been investigated as a prognos-
tic marker for CRC patients. Hypomethylation of LINE-1






hypomethylation of LINE-1 and poor prognosis is con-











methylation-specific PCR or pyrosequencing following
bisulfite treatment of DNA ; however, these method
showed the disadvantage of normal tissue contamination.
Methylation of LINE-1 in normal tissue is generally very
high and the contamination of normal tissue in the sam-
ple tended to show higher than real LINE-methylation of
tumor cells. This problem may be solved by immunohis-
tochemistry using specific antibody to LINE-1 to analyze
the LINE-1 protein expression rather than its methyla-
tion.
The mechanisms responsible for the relationship be-
tween LINE-1 expression and effectiveness of EGFR in-
hibitors are unknown. A study reported that LINE-1 ribo-
nucleoprotein particles have a role in telomere stability.
２６
It has also been reported that EGFR signaling has a role
in telomere length regulation, and longer telomere length
is a potential biomarker of the clinical outcome after anti-
EGFR antibody therapy in patients with RAS-wild type
CRC.
２７
Telomere regulation may be a candidate mecha-
nism underlying the association between LINE-1 expres-
sion and effects of EGFR inhibitors.
Growing evidence shows a pivotal role of LINE-1 ex-
pression in cancer development. Recent study reported
somatic retrotransposition in 2,954 cancer genomes from
38 histological cancer subtypes.
２８
As LINE-1 expression
followed by reverse-transcription and insertion into
genome is the most frequent type of retrotransposition,
LINE-1 expression may influence cancer characteristics.
Besides acting as a biomarker for the effects of EGFR in-
hibitors, cancer characteristics related to LINE-1-
dependent retrotransposition also have potential clinical
use for developing tailored medicine. A wide range of
clinical implications associated with LINE-1 expression
can be explored in future.
In conclusion, we showed an association between the
expression of LINE-1 mRNA and the effects of EGFR
inhibitors in CRC cells. Anti-EGFR antibodies and
small-molecule EGFR inhibitors may be able to exert
greater anticancer effects upon manipulation of LINE-1
expression. Further clarification of the mechanism under-
lying the association between the expression of LINE-1
mRNA and the effectiveness of EGFR inhibitors is re-
quired to develop more effective clinical therapies.
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